| Date | Time | Source | Announcement |
|---|---|---|---|
| 28 Jun 2010 | 07:00 AM | Presentation at the Internati | |
| 23 Jun 2010 | 07:40 AM | Replacement of Development re | |
| 23 Jun 2010 | 07:00 AM | Cephalon initiates critical s | |
| 17 Jun 2010 | 12:02 PM | Result of AGM | |
| 10 Jun 2010 | 10:55 AM | Annual Report and Accounts | |
| 19 May 2010 | 07:01 AM | Initiation Of Phase I/IIA Stu | |
| 19 May 2010 | 07:00 AM | Preliminary Results | |
| 08 Apr 2010 | 09:26 AM | Best Drug Development Company | |
| 05 Jan 2010 | 03:00 PM | Additional Listing | |
| 05 Jan 2010 | 07:00 AM | ING take 4% stake in ImmuPhar | |
| 03 Dec 2009 | 07:00 AM | R&D Symposium at the CNRS in | |
| 19 Nov 2009 | 07:00 AM | Positive Final Lupuzor Trial | |
| 19 Oct 2009 | 10:31 AM | 'Best Technology 2009' Award | |
| 09 Oct 2009 | 10:14 AM | Appointment of Joint Broker | |
| 29 Sep 2009 | 07:00 AM | Interim Results | |
| 21 Sep 2009 | 09:55 AM | 8th Annual Bio Investor Forum | |
| 17 Sep 2009 | 07:00 AM | JMP Healthcare Focus Conferen | |
| 24 Jul 2009 | 12:12 PM | Result of AGM | |
| 23 Jul 2009 | 04:17 PM | Directors' Dealings | |
| 30 Jun 2009 | 07:00 AM | Annual Report and Accounts | |
| 24 Jun 2009 | 07:00 AM | Preliminary Results | |
| 17 Jun 2009 | 07:00 AM | Piper Jaffray Europe Conferen | |
| 23 Mar 2009 | 07:00 AM | Directors' Dealings | |
| 04 Feb 2009 | 12:32 PM | Share Options | |
| 02 Feb 2009 | 02:33 PM | Cephalon license exercise | |
| 30 Jan 2009 | 07:00 AM | Successful trial results | |
| 22 Dec 2008 | 12:00 PM | further instalment of grant | |
| 25 Nov 2008 | 07:00 AM | Option Agreement with Cephalo | |
| 12 Nov 2008 | 07:00 AM | Grant Award | |
| 21 Oct 2008 | 09:31 AM | Patents Granted | |
| 17 Oct 2008 | 04:22 PM | Additional Listing and Total | |
| 25 Sep 2008 | 07:00 AM | Interim Results | |
| 05 Aug 2008 | 03:44 PM | AGM Result | |
| 10 Jul 2008 | 07:00 AM | Second Placing | |
| 02 Jul 2008 | 07:30 AM | Toxicology study | |
| 02 Jul 2008 | 07:00 AM | Fund Raising | |
| 30 Jun 2008 | 03:00 PM | Annual Report and Accounts | |
| 20 May 2008 | 07:00 AM | Pre-clinical Data | |
| 13 May 2008 | 06:00 AM | Trademark Approval | |
| 08 May 2008 | 07:00 AM | Preliminary Results | |
| 26 Feb 2008 | 07:00 AM | Phase IIb Trial of IPP-201101 | |
| 08 Jan 2008 | 07:00 AM | Novel Drug Candidate | |
| 18 Dec 2007 | 12:51 PM | Directors' Dealings | |
| 06 Dec 2007 | 07:01 AM | Initiation of Phase IIb trial | |
| 16 Nov 2007 | 12:28 PM | Appointment of Nomad | |
| 28 Sep 2007 | 07:02 AM | Interim Results | |
| 22 Aug 2007 | 07:00 AM | Compound Discovery | |
| 20 Aug 2007 | 10:17 AM | AIM Rule 26 | |
| 13 Aug 2007 | 04:17 PM | Directors' Dealing | |
| 06 Aug 2007 | 02:40 PM | Grant of Options |
ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France.
ImmuPharma listed on AIM under the ticker IMM.
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.
IMM share price listed in London at 1,190p in 2000.